Indian biotech startup Cellogen Therapeutics has successfully raised Rs 20 crore (approximately $2.3 million) from Kotak Alternate Asset Managers to propel its innovative cancer and gene therapy programs. This funding round, led by Kotak’s Life Sciences Fund I, marks a significant step for Cellogen as it seeks to advance its CAR-T clinical programs. The investment highlights the increasing interest in healthcare and life sciences ventures within India’s burgeoning startup ecosystem.
### About Cellogen Therapeutics
Founded in 2021 by Gaurav Kharya and Tanveer Ahmad, Cellogen Therapeutics is at the forefront of developing cell and gene therapies. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) technology to treat cancer and blood disorders. With the newly secured funding, Cellogen plans to enhance its CAR-T clinical programs, expand its gene therapy pipeline, and bolster its manufacturing and regulatory capabilities. The startup’s lead product is a bispecific, dual-antigen CAR-T therapy, which targets two cancer markers simultaneously, potentially reducing the risk of relapse compared to existing CAR-T treatments.
Related Posts
### The Funding Landscape and Competition
The investment from Kotak Alternate Asset Managers comes through its Kotak Life Sciences Fund I, which supports early and growth-stage healthcare and life sciences companies. Cellogen’s funding round reflects a growing trend in the Indian biotech sector, where investors are increasingly looking to support groundbreaking technologies that promise to address significant healthcare challenges. The startup is preparing for Phase I human clinical trials in collaboration with Christian Medical College Vellore, a move that could position it as a leader in the affordable CAR-T therapy segment.
Globally, CAR-T therapies are among the most advanced cancer treatments, but their high costs—ranging from $500,000 to $700,000—have limited access for many patients. Cellogen aims to drastically reduce these costs to between $60,000 and $70,000, making advanced cancer treatments more accessible to the Indian population. This focus on cost reduction and scalability could give Cellogen a competitive edge in both domestic and international markets.
### Implications for India’s Startup Ecosystem
Cellogen’s progress underscores the potential of India’s biotechnology sector and its capacity to innovate in high-impact areas like cancer treatment. The startup’s approach to creating cost-effective, scalable therapies aligns with the broader push within India to develop indigenous solutions to global health challenges. As the biotech sector continues to expand, startups like Cellogen are likely to attract more interest from both domestic and international investors looking for opportunities in cutting-edge medical technologies.
The involvement of major investors such as Kotak and Natco Pharma, which holds a 5.38% stake in Cellogen, indicates a strong vote of confidence in the company’s technology and business model. This could pave the way for more collaborations and partnerships within the industry, potentially leading to a more integrated and innovative biotech ecosystem in India.
Looking ahead, Cellogen Therapeutics is poised to make significant strides in the field of CAR-T therapies. For founders and investors in the Indian biotech sector, the company’s journey will be closely watched as an indicator of the viability and scalability of indigenous biotech innovations. The upcoming clinical trials will be a critical milestone, with successful outcomes likely to accelerate further investment and interest in India’s biotech capabilities.
